Hepato-gastroenterology最新文献

Scheepswrak Oude Inschot, Hoppa III 沉船，Hoppa III

Hepato-gastroenterology Pub Date : 2021-09-27 DOI: 10.34894/B33HGE

E. Jansma

引用次数: 0

Hepatocellular carcinoma. 肝细胞癌。

Hepato-gastroenterology Pub Date : 2020-10-31 DOI: 10.1002/0471463736.tnmp20.pub2

R. C. Johnson

引用次数: 0

Esophageal carcinoma. 食管癌癌。

Hepato-gastroenterology Pub Date : 2018-01-01 DOI: 10.1016/B978-0-323-47873-1.00046-2

R. Torphy, M. McCarter

引用次数: 0

The Rule of Law, Economic Efficiency and Social Justice: A Primer for the President 《法治、经济效率和社会正义:总统入门》

Hepato-gastroenterology Pub Date : 2018-01-01 DOI: 10.7916/D8-2HGE-8S79

J. Stiglitz

引用次数: 0

Predicting hepatocellular carcinoma recurrence and survival 预测肝细胞癌复发及生存

Hepato-gastroenterology Pub Date : 2016-01-01 DOI: 10.15761/GHE.1000111

Minuk Gy, Yu D, Holmes S, Uhanova J, Lipschitz J, McKay A

{"title":"Predicting hepatocellular carcinoma recurrence and survival","authors":"Minuk Gy, Yu D, Holmes S, Uhanova J, Lipschitz J, McKay A","doi":"10.15761/GHE.1000111","DOIUrl":"https://doi.org/10.15761/GHE.1000111","url":null,"abstract":"Background: Beta blockers can inhibit tumor growth and metastases, while necroinflammation can enhance these tumor properties. Objective: To determine whether beta blockers and necroinflammatory disease predict tumor recurrence and/or overall survival following potentially curative therapeutic interventions for patients with hepatocellular carcinoma (HCC). Methods: The medical records of 36 adults with non-metastatic HCC who had undergone surgical resections and/or radiofrequency ablation (RFA) were retrospectively reviewed. In addition to post-intervention beta blocker usage and serum alanine aminotransferase levels greater than 2xULN, other variables commonly associated with recurrences such as number and size of tumors, state of differentiation and vascular invasion were included in univariate and multivariate analyses for recurrence and survival. Results: Vascular invasion (OR 29.3, 95% CI 2.6-33.6) and surgical resection (OR 0.19, 95% CI 0.04-0.90) emerged from univariate (p=0.003 and 0.03 respectively) and multivariate (p=0.005 and 0.048 respectively) regression as predictors of tumor recurrence whereas beta blocker usage (OR 0.03, 95% CI 0.04-0.9, p=0.03) and tumor recurrence (OR 6.7, 95% CI 1.6-28.1, p=0.026) correlated with overall survival. Conclusions: Neither beta blocker usage nor serum ALT levels predict HCC recurrences, but beta blocker usage is associated with improved overall survival following potentially curative therapeutic interventions for HCC in adults. Correspondence to: Dr. G.Y. Minuk, Department of Internal Medicine, University of Manitoba, John Buhler Research Centre, 715 McDermot Ave., Canada, E-mail: gminuk@cc.umanitoba.ca","PeriodicalId":12985,"journal":{"name":"Hepato-gastroenterology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67464386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Interleukin 28B Polymorphism Predicts Treatment Outcome Among Egyptian Patients Infected With HCV Genotype 4. 白细胞介素 28B 多态性可预测感染了 HCV 基因型 4 的埃及患者的治疗效果。

Hepato-gastroenterology Pub Date : 2015-06-01

Mahmoud El-Bendary, Mustafa A Neamatallah, Mohamed Abd El-Maksoud, Maha Amin

引用次数: 0

Treatment of Gastric Metaplasia or Dysplasia by Endoscopic Radiofrequency Ablation: A Pilot Study. 内镜射频消融治疗胃化生或不典型增生:一项初步研究。

Hepato-gastroenterology Pub Date : 2015-05-01 DOI: 10.5754/HGE14816

W. Leung, D. Tong, S. Leung, F. S. Chan, T. Tong, R. S. Ho, K. Chu, S. Law

{"title":"Treatment of Gastric Metaplasia or Dysplasia by Endoscopic Radiofrequency Ablation: A Pilot Study.","authors":"W. Leung, D. Tong, S. Leung, F. S. Chan, T. Tong, R. S. Ho, K. Chu, S. Law","doi":"10.5754/HGE14816","DOIUrl":"https://doi.org/10.5754/HGE14816","url":null,"abstract":"BACKGROUND/AIMS\u0000Patients with gastric intestinal metaplasia and dysplasia are at increased risk of gastric cancer development. We tested the feasibility of using endoscopic radiofrequency ablation for the treatment of dysplasia and metaplasia in the stomach.\u0000\u0000\u0000METHODOLOGY\u0000Patients who had histologically confirmed low-grade gastric dysplasia or IM were recruited. Endoscopic RFA was performed at 8 week-intervals for a maximum of 3 sessions. All patients were followed up by endoscopy until 12 months post-RFA. The primary outcome was the complete eradication of dysplasia or IM on follow-up. Secondary outcome was adverse events related to RFA.\u0000\u0000\u0000RESULTS\u0000A total of 12 patients were recruited. Four patients had low-grade dysplasia and the remaining 8 patients had non-dysplastic IM at baseline. At one year after RFA, complete eradication of dysplasia was noted in four patients with low-grade dysplasia (100%). Gastric IM persisted in all patients with baseline metaplasia but the severity of IM improved in 6 (75%) patients. Endoscopic RFA was safe with minimal complications encountered.\u0000\u0000\u0000CONCLUSIONS\u0000RFA successfully eradicated low-grade dysplasia of the stomach. Gastric IM however persisted after RFA but most patients had evidence of histological improvement on follow up.","PeriodicalId":12985,"journal":{"name":"Hepato-gastroenterology","volume":"62 139 1","pages":"748-51"},"PeriodicalIF":0.0,"publicationDate":"2015-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71082583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

The significance of combined measurement of p53 antibody and other tumor markers for colorectal cancer after curative resection 结直肠癌根治性切除后p53抗体及其他肿瘤标志物联合检测的意义

Hepato-gastroenterology Pub Date : 2015-03-20 DOI: 10.5754/hge14874

川原大輔

引用次数: 0

Comparison of the level of intraoperative nociception between laparoscopic and open hepatic resection. 腹腔镜与开放式肝切除术术中痛觉水平的比较。

Hepato-gastroenterology Pub Date : 2015-03-01

Kazuma Hashimoto, Hiroki Miyawaki, Sachiko Iwayama, Nobutaka Kariya, Tsuneo Tatara, Munetaka Hirose

{"title":"Comparison of the level of intraoperative nociception between laparoscopic and open hepatic resection.","authors":"Kazuma Hashimoto, Hiroki Miyawaki, Sachiko Iwayama, Nobutaka Kariya, Tsuneo Tatara, Munetaka Hirose","doi":"","DOIUrl":"","url":null,"abstract":"Background/aims: Sufficient suppression of perioperative nociception is important for ensuring favorable postoperative outcomes. Although the level of nociception during laparoscopic surgery is generally lower than during laparotomy, there is insufficient evidence to support this for hepatic resection.Methodology: To develop a method to retrospectively evaluate the intraoperative nociceptive level, we collected data of intraoperative averaged values of heart rate, perfusion index, systolic blood pressure during three surgeries with different levels of intraoperative nociception. After we validated the utility of discriminant analysis using these variables for the retrospective evaluation of nociception during surgery, we performed this analysis in patients who underwent either laparoscopic or open hepatic resection.Results: Although there was a significant difference in discriminant score between the open and the laparoscopic hepatic resection groups before propensity score matching, discriminant score showed no significant difference between two groups after matching.Conclusions: The level of nociception during laparoscopic hepatic resection is likely similar to that during open hepatic resection. An assertive anti-nociceptive strategy might be required for laparoscopic procedures under general anesthesia, as with open procedures.","PeriodicalId":12985,"journal":{"name":"Hepato-gastroenterology","volume":"62 138","pages":"358-62"},"PeriodicalIF":0.0,"publicationDate":"2015-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33128569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Expression of vasohibin-2 in pancreatic ductal adenocarcinoma promotes tumor progression and is associated with a poor clinical outcome. 血管hibin-2在胰腺导管腺癌中的表达促进肿瘤进展，并与不良临床预后相关。

Hepato-gastroenterology Pub Date : 2015-03-01

Jung-Chul Kim, Kyung-Tae Kim, Jong-Tae Park, Hyun-Jong Kim, Yasufumi Sato, Hyung-Seok Kim

{"title":"Expression of vasohibin-2 in pancreatic ductal adenocarcinoma promotes tumor progression and is associated with a poor clinical outcome.","authors":"Jung-Chul Kim, Kyung-Tae Kim, Jong-Tae Park, Hyun-Jong Kim, Yasufumi Sato, Hyung-Seok Kim","doi":"","DOIUrl":"","url":null,"abstract":"This study aimed to assess the expression of vasohibin-2 (VASH2) in pancreatic ductal adenocarcinoma (PDAC) as a marker of tumor aggressiveness and its impact on tumor angiogenesis, proliferation, and clinical outcome. We examined the expression of the VASH2 gene in human pancreatic cell lines PANC-1 and MiaPaCa-2 by quantitative reverse transcription polymerase chain reaction (qRT-PCR) and immunocytochemistry. Fifty samples from patients with PDAC were immunostained with VASH2, CD34, and Ki-67 antibodies. Further, the immunoreactivity of VASH2 correlated with the pathological features, including microvessel density (MVD), tumor cell proliferation (Ki-67 labeling index), and survival. Forty-seven of the 50 samples from PDAC patients showed immunoreactivity for VASH2 along the tumor cell cytoplasm. Among the VASH2-positive samples, 22 were categorized as high VASH2 expression group, and this group had statistical significance with pN stage (p = 0.006), UICC stage (p = 0.033), tumor proliferation (p < 0.001), and MVD (p = 0.017). Moreover, patients with high VASH2 expression showed worse prognosis compared to those showing low VASH2 expression (overall logrank p = 0.003). Thus, our results suggested that overexpression of VASH2 accelerated the pace of tumor development toward a more serious malignant phenotype and was associated with a poor clinical outcome. VASH2 may be an important novel target for the management of PDAC after surgery.","PeriodicalId":12985,"journal":{"name":"Hepato-gastroenterology","volume":"62 138","pages":"251-6"},"PeriodicalIF":0.0,"publicationDate":"2015-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33253463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0